1. Home
  2. AARD vs NC Comparison

AARD vs NC Comparison

Compare AARD & NC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AARD
  • NC
  • Stock Information
  • Founded
  • AARD 2017
  • NC 1913
  • Country
  • AARD United States
  • NC United States
  • Employees
  • AARD N/A
  • NC N/A
  • Industry
  • AARD Biotechnology: Pharmaceutical Preparations
  • NC Coal Mining
  • Sector
  • AARD Health Care
  • NC Energy
  • Exchange
  • AARD Nasdaq
  • NC Nasdaq
  • Market Cap
  • AARD 216.6M
  • NC 247.6M
  • IPO Year
  • AARD 2025
  • NC N/A
  • Fundamental
  • Price
  • AARD $7.74
  • NC $33.43
  • Analyst Decision
  • AARD Strong Buy
  • NC
  • Analyst Count
  • AARD 4
  • NC 0
  • Target Price
  • AARD $31.50
  • NC N/A
  • AVG Volume (30 Days)
  • AARD 113.5K
  • NC 10.9K
  • Earning Date
  • AARD 01-01-0001
  • NC 03-05-2025
  • Dividend Yield
  • AARD N/A
  • NC 2.67%
  • EPS Growth
  • AARD N/A
  • NC N/A
  • EPS
  • AARD N/A
  • NC 4.55
  • Revenue
  • AARD N/A
  • NC $237,708,000.00
  • Revenue This Year
  • AARD N/A
  • NC N/A
  • Revenue Next Year
  • AARD N/A
  • NC N/A
  • P/E Ratio
  • AARD N/A
  • NC $7.62
  • Revenue Growth
  • AARD N/A
  • NC 10.67
  • 52 Week Low
  • AARD $7.74
  • NC $25.19
  • 52 Week High
  • AARD $19.58
  • NC $34.78
  • Technical
  • Relative Strength Index (RSI)
  • AARD N/A
  • NC 52.67
  • Support Level
  • AARD N/A
  • NC $32.83
  • Resistance Level
  • AARD N/A
  • NC $34.67
  • Average True Range (ATR)
  • AARD 0.00
  • NC 1.08
  • MACD
  • AARD 0.00
  • NC 0.01
  • Stochastic Oscillator
  • AARD 0.00
  • NC 46.23

About AARD Aardvark Therapeutics Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

About NC NACCO Industries Inc.

NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments that are coal mining, North American mining (NA mining), and minerals management. The majority of its revenue is from the coal mining segment. This segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The NA mining segment provides value-add contract mining and services for producers. Minerals management generates income from royalty-based leases by acquiring and promoting oil, gas, and coal mineral interests. The company is diversifying beyond coal mining due to political and economic pressures associated with carbon emissions.

Share on Social Networks: